Oxana V Crysler (Oxana Crysler)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Top Venues

Cancer research communications

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Mark Yarchoan, John D Powderly, Bruno R Bastos, Thomas Benjamin Karasic, Oxana V Crysler, Pamela N Munster, Meredith A McKean, Leisha A Emens, Yvonne M Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W Dubensky, Sam H Whiting, Susanna V Ulahannan
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer research communications 4 (4) (2024)
Arathi Mohan, Kent A Griffith, Fulei Wuchu, David B Zhen, Chandan Kumar-Sinha, Oxana V Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, Srinadh Choppara, Minal Nenwani, Arul M Chinnaiyan, Deepak Nagrath, Mark M Zalupski, Vaibhav Sahai
Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)